NovoCure Limited
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Revenue | $177.0M | $82.9M | $33.1M | $15.5M | $10.4M |
| Cost of Revenue | $55.6M | $39.9M | $20.6M | $10.0M | $7.0M |
| Gross Profit | $121.4M | $36.6M | $12.5M | $5.5M | $3.3M |
| Gross Margin | 68.6% | 44.2% | 37.7% | 35.2% | 32.3% |
| Operating Expenses | |||||
| Research & Development | $38.1M | $41.5M | $43.7M | $40.4M | $34.8M |
| SG&A Expense | $59.1M | $51.0M | $33.9M | $24.1M | $16.6M |
| Operating Income | $-39.3M | $-115.3M | $-104.0M | $-80.2M | $-64.5M |
| Operating Margin | -22.2% | -139.1% | -314.3% | -517.5% | -622.3% |
| Interest Expense | $11.7M | $7.3M | $3.2M | $287.0K | $12.8M |
| Pretax Income | $-48.5M | $-121.5M | $-107.1M | $-80.3M | $-77.0M |
| Income Tax Expense | $13.2M | $10.4M | $4.4M | $382.0K | $353.0K |
| Net Income | $-61.7M | $-131.8M | $-111.6M | $-80.7M | $-77.4M |
| Net Margin | -34.8% | -159.1% | -337.2% | -520.9% | -746.9% |
| EPS (Basic) | $-0.70 | $-1.54 | $-3.67 | $-6.46 | $-6.73 |
| EPS (Diluted) | $-0.70 | $-1.54 | $-3.67 | $-6.46 | $-6.73 |
| Shares Outstanding (Basic) | 89.5M | 87.1M | 83.8M | 13.4M | — |
| Shares Outstanding (Diluted) | 89.5M | 87.1M | 83.8M | 13.4M | — |
| Dividends Per Share | — | — | — | — | — |